Luminex (Luminex) COGS-to-Revenue : 0.40 (As of Mar. 2021)

View and export this data going back to 2000. Start your Free Trial

What is Luminex COGS-to-Revenue?

Luminex's Cost of Goods Sold for the three months ended in Mar. 2021 was $44.2 Mil. Its Revenue for the three months ended in Mar. 2021 was $110.7 Mil.

Luminex's COGS to Revenue for the three months ended in Mar. 2021 was 0.40.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Luminex's Gross Margin % for the three months ended in Mar. 2021 was 60.04%.

Luminex COGS-to-Revenue Historical Data

The historical data trend for Luminex's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Luminex COGS-to-Revenue Chart

Luminex Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

COGS-to-Revenue

Get a 7-Day Free Trial

0.34

0.35

0.38

0.45

0.41

Luminex Quarterly Data
	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21
COGS-to-Revenue	Get a 7-Day Free Trial															0.44	0.36	0.40	0.42	0.40

Luminex COGS-to-Revenue Calculation

Luminex's COGS to Revenue for the fiscal year that ended in Dec. 2020 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	169.544	/	417.396
	=	0.41

Luminex's COGS to Revenue for the quarter that ended in Mar. 2021 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	44.227	/	110.688
	=	0.40

Luminex (NAS:LMNX) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Luminex's Gross Margin % for the three months ended in Mar. 2021 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	44.227 / 110.688
	=	60.04 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Luminex COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Luminex's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Luminex (Luminex) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Luminex Corp (NAS:LMNX) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

12212 Technology Boulevard, Suite 130, Austin, TX, USA, 78727

Website

https://www.luminexcorp.com

Luminex Corp develops, manufactures, and sells proprietary biological testing technologies and products to testing laboratories. It primarily serves the life sciences industries by selling products used by laboratory professionals and clinical laboratories in performing diagnostics, drug research and discovery, and clinical tests on patients. Luminex's market segments mainly include Infectious disease, Personalized medicine, and Human genetics. It offers various solutions in diverse markets, including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic and proteomic research, and food safety. The vast majority of the company's revenue is earned in the United States. The products offered are xMAP Products, ARIES Products and VERIGENE Products, among others.

Executives

Harriss T Currie	officer: SVP, Finance & CFO	12212 TECHNOLOGY BOULEVARD AUSTIN TX 78727
Todd C. Bennett	officer: SVP, Global Sales & Cust Ops	12212 TECHNOLOGY BLVD. AUSTIN TX 78727
Stephen L. Eck	director	12212 TECHNOLOGY BLVD., AUSTIN TX 78727
Edward A Ogunro	director
Eric Shapiro	officer: SR VP, GLOBAL MARKETING	12212 TECHNOLOGY BLVD. AUSTIN TX 78727
Nachum Shamir	director, officer: President & CEO	12212 TECHNOLOGY BLVD, AUSTIN TX 78727
Rew Richard W. Ii	officer: SVP, Gen Counsel & Corp Secy	7000 WEST WILLIAM CANNON, BUILDING ONE, AUSTIN TX 78735
Nancy Fairchild	officer: SVP, Human Resources	12212 TECHNOLOGY BLVD. AUSTIN TX 78727
G Walter Lowenbaum	director	C/O 3D SYSTEMS CORPORATION, 333 THREE D SYSTEMS CIRCLE, ROCK HILL SC 29730
Randall Myers	officer: SVP, Global Mfg and Quality	12212 TECHNOLOGY BOULEVARD AUSTIN TX 78727
Charles J. Collins	officer: SR VP, R&D - US	12212 TECHNOLOGY BLVD. AUSTIN TX 78727
Dijuana K Lewis	director	120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204
Jim D Kever	director	C/O 3D SYSTEMS, 26081 AVENUE HALL, VALENCIA CA 91355
Thomas W Erickson	director	OMEGA HEALTHCARE INVESTORS INC, 900 VICTORS WAY STE. 350, AMM ARBER MI 48108
Kenneth A Samet	director	800 KING FARM BOULEVARD, 4TH FLOOR, ROCKVILLE MD 20850